News
Emmes is excited to share the significant progress being made in clinical studies we undertake for clients and to give you a look inside some of our own news.
Press Releases
06/21/2022
Emmes
New Mountain Capital Announces Growth Partnership with Emmes
Partnership to Support Emmes’ Next Phase of Tech-Enabled Growth
06/16/2022
Emmes
Emmes Supports Groundbreaking Anal Cancer Study Sponsored by the National Cancer Institute
Emmes, a global, full-service clinical research organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that a team of its researchers contributed to a successful AIDS Malignancy Consortium (AMC) study.
05/16/2022
Emmes
Emmes Supports Landmark mRNA COVID-19 Vaccine Trial in Sub-Saharan Africa
Emmes, a global, full-service clinical research organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that it is providing data, statistical analysis, and project management support for new research that will test the Moderna mRNA vaccine at more than 50 sites in South and East Africa.
05/11/2022
Emmes
Emmes launches Advantage eClinical as a standalone cloud native clinical technology platform
The cloud platform will empower biotech companies and CROs with an integrated solution for clinical data management and is supported by Emmes specialist data management teams.
04/27/2022
Emmes
Emmes and Casimir Announce Research About a Novel, Home-Based Assessment for Duchenne Muscular Dystrophy
Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that Casimir’s research on the development of the Duchenne Video Assessment (DVA) scorecards was published in PLOS ONE. Emmes acquired Casimir in March 2022, and the group is now part of Emmes’ Rare Disease Center, Orphan Reach™.
03/10/2022
Emmes
Emmes Acquires Casimir, Its Fourth Major Acquisition
Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced that it has acquired Casimir, a U.S.-based CRO.
02/02/2022
Emmes
Emmes Supports New Collaboration to Accelerate COVID-19 Research for Children
Emmes, a global, full-service Clinical Research Organization dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced its role as a Data Coordinating Center on a team whose work has accelerated pediatric COVID-19 research through the Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POP02).
12/21/2021
Emmes
Emmes Acquires Institut Dr. Schauerte, Entering Real World Evidence Market
Company’s Third Major Acquisition Expands European Presence in Germany; Adds New Electronic Data Capture Tool to Enhance Real World Evidence Research.
11/29/2021
Emmes
Emmes Announces Completion of Third ACTT Clinical Trial for COVID-19
Emmes today announced that it conducted the data and statistical analysis for the third iteration of the Adaptive COVID-19 Treatment Trial (ACTT-3), using its proprietary Advantage eClinical system. The ACTT-3 trial assessed the efficacy and safety of interferon beta-1a plus remdesivir compared to remdesivir alone in hospitalized adults with COVID-19.
11/15/2021
Emmes
Emmes and MedGenome Launch Genomics Strategic Partnership Focused on Advancing Rare Disease Research
Emmes, a global, full-service Clinical Research Organization (CRO) dedicated to supporting the advancement of public health and biopharmaceutical innovation, today announced a partnership with MedGenome aimed at accelerating breakthrough treatments, powered by human genomics, for rare disease patients.
11/03/2021
Emmes
Emmes launches Orphan Reach™: Emmes’ Rare Disease Center
Emmes – a full service, global clinical research organization (CRO) – is launching its new center, Orphan Reach™ as a unique ‘rare CRO’. The new rare disease center will incorporate Emmes’ world class reputation in public health research across the public sector and biopharmaceutical industry, with the expertise of Orphan Reach, a UK-based specialty CRO acquired by Emmes in May 2021.
09/20/2021
Emmes
Emmes Standardizes on Veeva Development Cloud to Streamline Product Development
Emmes and Veeva Systems (NYSE: VEEV) today announced that Emmes is standardizing on Veeva Development Cloud applications across functional areas to enable greater speed and compliance. The company will use applications in Vault Clinical, Vault Quality, and Vault Safety suites to establish a technology foundation for delivering clinical research and pharmacovigilance services to its global customers.